Breaking Finance News

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to Hold in a statement released on 10/05/2016.

Boasting a price of $0.86, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) traded 1.13% higher on the day. With the last close down -8.53% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. AVEO Pharmaceuticals, Inc. has recorded a 50-day average of $0.91 and a two hundred day average of $0.95. Volume of trade was down over the average, with 83,636 shares of AVEO changing hands under the typical 189,598

Performance Chart

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

With a total market value of $0, AVEO Pharmaceuticals, Inc. has with a one year low of $0.81 and a one year high of $1.47 .

A total of 1 analyst has released a research note on AVEO. One analyst rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $3.00.

More About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *